Valion Bio (VBIO)

• Market cap: $2.45M
• 1 day: -2.25%
• 5 days: -14.78%
• 1 month: -20.21%
• 3 months: -5.43%
• 6 months: -58.14%
• Year to date: -46.06%
• 1 year: -81.76%
• 5 years: -99.99%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

Employees: 52